The Extracellular Domain of the β2 Integrin β Subunit (CD18) Is Sufficient for Escherichia coli Hemolysin and Aggregatibacter actinomycetemcomitans Leukotoxin Cytotoxic Activity

Laura C. Ristow, Vy Tran, Kevin J. Schwartz, Lillie Pankratz, Andrew Mehle, John-Demian Sauer, Rodney A. Welch

*Department of Medical Microbiology and Immunology, University of Wisconsin—Madison, Madison, Wisconsin, USA

ABSTRACT The Escherichia coli hemolysin (HlyA) is a pore-forming exotoxin associated with severe complications of human urinary tract infections. HlyA is the prototype of the repeats-in-toxin (RTX) family, which includes LtxA from Aggregatibacter actinomycetemcomitans, a periodontal pathogen. The existence and requirement for a host cell receptor for these toxins are controversial. We performed an unbiased forward genetic selection in a mutant library of human monocytic cells, U-937, for host factors involved in HlyA cytotoxicity. The top candidate was the β2 integrin β subunit. Δβ2 cell lines are approximately 100-fold more resistant than wild-type U-937 cells to HlyA, but remain sensitive to HlyA at high concentrations. Similarly, Δβ2 cells are more resistant than wild-type U-937 cells to LtxA, as Δβ2 cells remain LtxA resistant even at >1,000-fold-higher concentrations of the toxin. Loss of any single β2 integrin α subunit, or even all four α subunits together, does not confer resistance to HlyA. HlyA and LtxA bind to the β2 subunit, but not to αL, αM, or αx in far-Western blots. Genetic complementation of Δβ2 cells with either β2 or β2 with a cytoplasmic tail deletion restores HlyA and LtxA sensitivity, suggesting that β2 integrin signaling is not required for cytotoxicity. Finally, β2 mutations do not alter sensitivity to unrelated pore-forming toxins, as wild-type or Δβ2 cells are equally sensitive to Staphylococcus aureus α-toxin and Proteus mirabilis HpmA. Our studies show two RTX toxins use the β2 integrin β subunit alone to facilitate cytotoxicity, but downstream integrin signaling is dispensable.

IMPORTANCE Urinary tract infections are one of the most common bacterial infections worldwide. Uropathogenic Escherichia coli strains are responsible for more than 80% of community-acquired urinary tract infections. We have known for nearly a century that severe infections stemming from urinary tract infections, including kidney or bloodstream infections are associated with expression of a toxin, hemolysin, from uropathogenic Escherichia coli, how hemolysin functions to enhance virulence is unknown. Our research defines the interaction of hemolysin with the β2 integrin, a human white cell adhesion molecule, as a potential therapeutic target during urinary tract infections. The E. coli hemolysin is the prototype for a toxin family (RTX family) produced by a wide array of human and animal pathogens. Our work extends to the identification and characterization of the receptor for an additional member of the RTX family, suggesting that this interaction may be broadly conserved throughout the RTX toxin family.

KEYWORDS cytotoxicity, hemolysin, integrins, leukotoxin, RTX toxin
>50% of hospital-acquired UTIs, which average nearly 1 million cases annually (1, 2). Nearly a century ago, epidemiological studies revealed that UPEC strains were more likely than commensal E. coli to express a hemolytic factor, now known as hemolysin (HlyA) (3). The presence of the hlyA gene in the genome of clinical isolates correlates with severity of infection as hlyA is carried in 31 to 48% of E. coli strains recovered from uncomplicated UTIs, but in pyelonephritis or urosepsis isolates, 50 to 78% of strains contain the gene (4–6). A precise role for HlyA in progression of these infections is undefined in experimental models. Significant differences in exfoliation and hemorrhage in the murine bladder at early time points are observed in mice intraurethrally inoculated with HlyA-expressing compared to HlyA-deficient UPEC, but no significant differences were observed in colonization or dissemination to the kidneys (7). The importance of HlyA as a virulence factor is clear, as it enhances lethal sepsis following intravenous inoculation, but an animal model of progression to urosepsis from a urinary tract infection does not exist (8).

A precise mechanism for the cytotoxic activity of HlyA has remained controversial despite decades of research. In vitro, HlyA is cytotoxic to a wide range of hosts and cell types at high concentrations, fortifying the argument that the pore-forming protein has nonspecific cytotoxic activity (3, 9, 10). At sublytic concentrations, stable insertion of HlyA in the membrane induces changes in the host cell, including inactivation of an important host cell regulator, Akt, induction of the serine protease, mesotrypsin, and activation of caspases—all activities through which the toxin may contribute to UPEC virulence independent of direct lytic destruction of tissue (11, 12). In 1997, Lally et al., using a panel of antibodies against HL-60 surface proteins, identified an HlyA cytolysis-blocking antibody that bound the α2β2 integrin heterodimer (the CD11a/CD18 encoded by ITGAL/ITGB2) subunits of LFA-1 [i.e., lymphocyte function-associated antigen-1]) (13). Ectopic expression of the heterodimeric integrin on K562 cells that do not natively express β2 integrins conferred increased sensitivity to HlyA cytotoxic activity (13). Additionally, Morova et al. determined that the glycosylation state of α2β2-expressing cells is important for HlyA cytotoxic activity (14). In contrast, Valeva et al. contend that the expression of α2β2 enhances sensitivity of cells to all pore-forming toxins, suggesting that HlyA activity is not receptor dependent (15). Most recently, Munksgaard et al. demonstrated that K562 cells transfected with α2β2 are no more sensitive to HlyA than the parental cell line (16). Although the interaction of HlyA with β2 integrins has been described in several reports, the significance and reproducibility of this across the field have remained debatable and the assessment of HlyA interaction with each member of the β2 integrin family incomplete.

HlyA is the prototypical member of the RTX (repeats-in-toxin) family, a large family of conserved proteins found across Gram-negative bacteria (17). Like HlyA, several other RTX toxin family members found in human-pathogenic bacteria have reported β2 integrin family specificity (13). LtxA is expressed by the human pathogen Aggregatibacter actinomycetemcomitans, which can cause a variety of infections. The importance of LtxA as a virulence factor is most apparent in A. actinomycetemcomitans associated with an aggressive form of periodontitis in young adults, as the toxin is produced at 10- to 20-fold-higher levels than in other infectious isolates (18, 19). Similar to historical HlyA reports, literature describing the specificity of LtxA for the α2β2 integrin heterodimer is controversial, as Dileepan et al. define the specificity of LtxA for the β2 subunit alone, whereas in multiple reports, the specificity of LtxA for the complete α2β2 integrin heterodimer or the α2 subunit, narrowed to specific β-sheets of the α2 subunit, is described (13, 20–22). LtxA activity can be inhibited with peptides generated based on the defined interacting domain of LtxA with α2-subunit β-sheets (22). Additionally, Nygren et al. described the interaction of LtxA with the cytoplasmic domains of the α2β2 integrin heterodimer, hypothesized to follow internalization of LFA-1/LtxA after the initial extracellular interaction (22, 23). Similar to studies with HlyA, LtxA has been described to interact with β2 integrins in nonnative β2-expressing cells in some studies, but a thorough examination of the repertoire of β2 integrin-LtxA interactions in the context of native β2 integrin expression has not been assessed.
In this work, we performed an unbiased genome-wide positive selection in the U-937 human monocytic cell line to identify host factors that contribute to the cytotoxic activity of HlyA. The top hit from our selection was the β92 subunit of the β2 integrin family. We have characterized that for HlyA and LtxA, the presence of the β92 integrin subunit alone is sufficient to enhance cytotoxic activity of the toxins. Additionally, signaling downstream of the β92 subunit is not necessary for HlyA- or LtxA-mediated cytotoxicity, as a complemented strain expressing a cytoplasmic tail-deficient β92 subunit is equally sensitive to HlyA and LtxA cytotoxic activities. Our study provides a thorough examination of the importance of β2 integrins in the context of HlyA- or LtxA-mediated cytotoxicity and may provide therapeutic targets for disrupting toxin interactions with the host for both pathogenic bacteria.

RESULTS

GeCKO library selection identified host factors that contribute to HlyA cytotoxic activity. Multiple human cell lines historically used in UPEC research were examined for susceptibility to HlyA, including human bladder epithelial cells (5637), human kidney epithelial cells (A498), human T lymphocytes (Jurkat), human B lymphocytes (Raji), and human monocytes (U-937). The cytotoxic activity of HlyA was characterized with HlyA at a range of concentrations, and the state of cellular redox potential as a proxy for cell viability was monitored by XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide salt] assay (Fig. 1A). As previously described, HlyA was cytotoxic at high concentrations across all cell types examined, but interestingly, differences in the concentration at which 50% of cells are killed (cytotoxic dose 50 [CD50]) ranged up to 100-fold, suggesting the existence of factors that contribute to cell line specificity (3, 9, 10).
To identify host-specific factors required for the cytotoxic activity of HlyA, we focused on one of the most HlyA-sensitive lines examined, U-937 cells (Fig. 1A). We generated a Genome-scale CRISPR Knock-Out (GeCKO) library using the GeCKO v2 library developed in the Zhang lab (24). This library contains over 120,000 single guide RNAs (sgRNAs), with 6 sgRNAs targeting each of 19,050 genes and 4 sgRNAs targeting each of 1,864 microRNAs (miRNAs) (24). We performed two serial selections of $6 \times 10^7$ cells (500× representation of each sgRNA) of the U-937 mutant library with a concentration of HlyA at which nearly 100% of parental U-937 cells were killed, in biological triplicate (see Fig. S1 in the supplemental material). Genomic DNA was isolated, and deep sequencing of amplified and barcoded sgRNAs from each replicate was performed to identify enriched sgRNAs in both the single- and double-treated populations compared to the untreated parental library. Enriched sgRNAs were ranked using the Model-based Analysis of Genome-scale CRISPR-Cas9 Knockout (MAGECK) tool, which was exclusively designed to analyze results from GeCKO library selections (25). Four of the six sgRNAs targeting the integrin subunit $\beta_2$ gene (ITGB2) were positively selected in all HlyA-treated libraries, comprising up to 84% of the sequence reads from one of the populations and generating the most robust hit by several orders of magnitude in our selection (Fig. 1B; see Fig. S2 in the supplemental material). The $\beta_2$ integrin family includes the surface-expressed heterodimeric proteins $\alpha_2\beta_2$ (CD11a/CD18 [encoded by ITGAD/ITGB2]), $\alpha_5\beta_2$ (CD11a/CD18 [encoded by ITGAL/ITGB2]), subunits of LFA-1 [lymphocyte function associated antigen-1]), $\alpha_m\beta_2$ (CD11b/CD18 [encoded by ITGAM/ITGB2]), subunits of Mac-1 [macrophage-1 antigen]), and $\alpha_x\beta_2$ (CD11c/CD18 [encoded by ITGAX/ITGB2]), p150/95), all of which are exclusively expressed on leukocytes (26). Despite comparable representation in the parental libraries of sgRNAs targeting each of the four $\alpha$ subunits relative to the $\beta_2$ subunit (Fig. 1B and 1C), none were enriched across three biological replicates (see Fig. S3 in the supplemental material). Taken together, the selection and sequencing results suggest that at least one isoform of the $\beta_2$ integrin family mediates increased sensitivity of U-937 cells to HlyA activity, but that no single $\alpha\beta$ pair is necessary.

Enhanced HlyA cytotoxic activity in the presence of the $\beta_2$ integrin family is redundant among different $\alpha$ subunits. We generated clonal targeted CRISPR/Cas9-mediated knockout U-937 cells deficient in each of the four individual $\alpha$ subunits and the $\beta_2$ subunit, using 3 unique sgRNA sequences per subunit from the GeCKO v2 library. Potential clones were screened for disruption of the target gene by IDAA (indel detection by amplicon analysis) and loss of target gene expression by flow cytometry and confirmed by sequencing (see Table S1 in the supplemental material) (27). The HlyA CD$_{50}$ was determined for each clonal knockout cell line as in Fig. 1. No difference in sensitivity to HlyA was observed in any $\Delta \alpha$ cell line, which confirmed selection results that no single $\alpha$ subunit is necessary for HlyA activity (Fig. 2A). In contrast, a clonal $\Delta \beta_2$ cell line demonstrated nearly a 100-fold increase in CD$_{50}$ of HlyA (Fig. 2A), which correlated with our selection results and was consistent with the difference between HlyA cytotoxicity in U-937 cells compared to human bladder or kidney epithelial cells (natively $\beta_2^{\sim\sim}$) (Fig. 1A).

To assess the sufficiency of each $\alpha\beta$ pair in mediating sensitivity to HlyA, we set out to generate cell lines deficient in all combinations of two, three, or all four $\alpha$ subunits to assess the effect on the HlyA CD$_{50}$. Confirmed single-$\alpha$ knockouts that constitutively express the Cas9 nuclease were electroporated with sgRNA to target additional $\alpha$ subunits. Multi-$\alpha$ knockouts were generated in a stepwise fashion, with single-cell clones obtained and knockouts confirmed for each $\alpha$ subunit in turn. Although we generated multiple combinations of double ($\Delta\alpha_{DL}$, $\Delta\alpha_{OX}$, $\Delta\alpha_{LM}$, and $\Delta\alpha_{LX}$) and triple ($\Delta\alpha_{DLLM}$, $\Delta\alpha_{DOLS}$) $\alpha$ subunit knockouts and hypothesized that the triple $\alpha$ subunit knockouts would be the most informative regarding the specificity or redundancy between the $\beta_2$ family integrins for HlyA activity, a quadruple $\alpha$ subunit knockout revealed the most unexpected result. Integrins are characterized as requisite heterodimers for functional surface expression (28, 29). Therefore, we hypothesized that a quadruple $\alpha$ subunit knockout ($\Delta\alpha_{DLMAX}$) would phenocopy a $\beta_2$ knockout both in a
complete loss of surface expression of $\beta_2$ and in increased resistance to HlyA. Interestingly, a quadruple $\alpha$ knockout cell line only had a minor increase in resistance to HlyA compared to wild-type U-937 cells (Fig. 2B) and retained a small population of $\beta_2$ on the cell surface, observed by flow cytometry on intact cells (Fig. 2C). In the $\Delta \alpha_{DL\alpha\beta}$ background, we confirmed that the observed phenotype was due to the presence of $\beta_2$ and not unintentional mutations acquired during the mutagenesis strategy by additionally knocking out the $\beta_2$ subunit ($\Delta \alpha_{DL\alpha\beta}$). The $\Delta \alpha_{DL\alpha\beta} \beta_2$ cell line phenocopies a single $\beta_2$ subunit knockout both in resistance to HlyA cytotoxic activity (Fig. 2B) and loss of $\beta_2$ expression (Fig. 2C), confirming that the presence of $\beta_2$ confers sensitivity to HlyA cytotoxic activity.

The sensitivity of the U-937 $\Delta \alpha_{DL\alpha\beta}$ cells together with the resistance of the $\Delta \alpha_{DL\alpha\beta} \beta_2$ cells suggested that HlyA interaction with $\beta_2$, in the absence of any known $\alpha$ subunit binding partners, was sufficient to confer sensitivity. To test this hypothesis, we performed a far-Western blot with HlyA against various $\beta_2$ integrin heterodimers. Far-Western blots with recombinant $\alpha_\alpha \beta_2$, $\alpha_\alpha \beta_2$, and $\alpha_\alpha \beta_2$ protein demonstrate that HlyA interacts directly with the $\beta_2$ subunit, but not any of the $\alpha$ subunits (Fig. 2D). The resistance of $\beta_2$ integrin-deficient mutant cells combined with far-Western blotting...
suggests that HlyA interaction with the β_2 integrin subunit is sufficient for cytotoxicity in U-937 cells.

β_2 subunit enhancement of HlyA cytotoxic activity is not dependent on downstream signaling. To determine if β_2 integrin signaling is required for HlyA-induced cytotoxicity, we generated U-937 Δβ_2 complemented strains with either wild-type β_2 or a β_2 subunit lacking the cytoplasmic tail (Fig. 3A). Although we were unable to achieve wild-type levels of β_2 expression on the surface with either wild-type or the cytoplasmic tail deletion (Fig. 3B), both complements restore sensitivity to HlyA activity, suggesting that the cytotoxic activity of HlyA requires little β_2 on the surface of cells and does not require signaling downstream of β_2 integrins (Fig. 3C).

The β_2 integrin β subunit specifically enhances cytotoxic activity of a related RTX toxin. As the prototypic member of the RTX toxin family, HlyA’s structure and function are shared by related toxins present in many different human and animal pathogens. To determine the requirement of β_2 integrins for an additional RTX toxin family member, we utilized the mutants described above to assess sensitivity to LtxA from _Aggregatibacter actinomycetemcomitans_. The indicated cell lines were challenged with LtxA for 3 h before determination of the CD _50_. Unlike HlyA, LtxA activity is redundant among the three of the four α subunits compared to wild-type U-937 cells (Fig. 4A), but is significantly reduced in the absence of α (or of all four α subunits, Δα) (Fig. 4A and B). The increased resistance of these cell lines is inversely correlated with the expression of β_2 on their cell surface (Fig. 4C and 2C). A dramatic increase in resistance to LtxA is observed in the absence of the β subunit of the β_2 integrin family, as no activity was observed on Δβ_2 or Δαβ_2 U-937 cells despite
The enhancement of cytotoxic activity in the presence of β2 integrins does not extend to all pore-forming toxins. Previous work suggested that the expression of β2 integrins not only increases sensitivity of cells to HlyA, but also increases it to multiple, unrelated pore-forming toxins (15). Although that result strongly supported a non-β2-specific activity of HlyA, the investigators relied on the presence and absence of recombinant expression of αβ2 in nonnative β2-expressing cells. To assess the role of β2 integrins in sensitizing native β2-expressing cells to diverse pore-forming toxins, the indicated cell lines were treated with *Staphylococcus aureus* α-toxin for 24 h before determination of the CD50. Knockout of any α subunit or β2 did not significantly affect the sensitivity of cells to α-toxin (Fig. 5A). Similarly, the indicated cell lines were treated with culture supernatant containing the unrelated pore-forming toxin HpmA from *Proteus mirabilis* for 1 h before determination of the CD50. All cell lines were equally susceptible to the pore-forming cytotoxic activity of HpmA, and expression of β2 being treated with >1,000-fold concentrations higher than the CD50 of LtxA on wild-type U-937 cells (Fig. 4B; see Fig. S4 in the supplemental material). The dependence of LtxA on the presence and abundance of the β subunit on the surface of cells for cytotoxic activity is supported by a far-Western blot analysis of LtxA interaction with recombinant integrins, in which LtxA phenotypically copied HlyA with interaction solely with the β subunit (Fig. 4D). Complementation of Δβ2 U-937 cells with the wild type or a cytoplasmic tail deletion of the β2 subunit restores sensitivity to LtxA cytotoxic activity, indicating that like HlyA, LtxA does not require signaling downstream of β2 integrins (Fig. 4E).
integrins did not significantly alter the CD_{50} (Fig. 5B). These results suggest that the presence of \(\beta_2\) integrins does not nonspecifically enhance the cytotoxic activity of pore-forming toxins.

**DISCUSSION**

The UPEC HlyA has long been appreciated as an important virulence factor in complicated UTIs that lead to pyelonephritis or urosepsis. Despite the efforts of many different laboratories, the role that this toxin plays in uropathogenesis remains poorly understood. We began this study with side-by-side comparisons of the sensitivity of different cultured human cell types to HlyA. At high concentrations, HlyA is ubiquitously cytotoxic. By examining the cytotoxic effects of HlyA over a range of concentrations, we observed significant differences in the activity of the toxin across a variety of human cell lines, with leukocytes (monocyte-like and lymphocyte-like cells) 100-fold more sensitive to the toxin than either bladder or kidney epithelial cells. This observation provided the rationale to perform a forward genetic screen using CRISPR/Cas9 technology to identify host cell factors involved in HlyA-mediated cytotoxic activity using the human monocyte-like cell line U-937. Despite extensive mutagenic coverage of the entire genome, our selection and enrichment yielded multiple mutant alleles of a single gene, \(ITGB2\), which encodes the \(\beta_2\) subunit of the \(\alpha_\text{L}\beta_2\) integrin heterodimer.

Although the role of \(\alpha_\text{L}\beta_2\) as a specific receptor for HlyA is controversial, several groups demonstrate that the presence of this \(\beta_2\) receptor on cells increases sensitivity to HlyA, so we predicted we would observe mutants in genes encoding both \(\alpha_\text{L}\) and \(\beta_2\) subunits (13, 15). While we did recover the \(\beta\) subunit of the \(\alpha_\text{L}\beta_2\) integrin heterodimer, the absence of \(\alpha_\text{L}\) was unexpected, as integrins canonically function as obligate heterodimers and require an \(\alpha\) subunit and \(\beta\) subunit for proper processing and expression on the surface of cells (28, 29). We confirmed that the U-937 mutant library contained multiple guide RNAs targeting the \(ITGAL\) gene that encodes the \(\alpha_\text{L}\) subunit, but they did not appear in our selected population. Previous work with \(\alpha_\text{L}\beta_2\) and several RTX toxins, including HlyA and LtxA, was performed by ectopic expression of \(\alpha\) and \(\beta_2\) integrin subunit genes in nonleukocyte cells or by the addition of \(\alpha\)-encoding cDNA to ethyl methanesulfonate (EMS)-mutagenized Jurkat cells that lacked \(\beta_2\) surface expression (13, 15, 30). Perhaps contributing to the controversy of the role of specific \(\beta_2\) integrins in mediating HlyA cytotoxicity, no unbiased assessment of the role of all \(\beta_2\) integrins in HlyA-mediated toxicity has been performed. Our selection results indicated that the \(\alpha\) subunits are redundant for HlyA cytotoxic activity in that no single \(\alpha\beta\) pair
was necessary for HlyA cytotoxic activity. We proceeded to generate directed mutations in each of the α-subunit-encoding genes and the β₂ integrin β-subunit-encoding gene. None of the α subunit-encoding gene mutants were altered in HlyA sensitivity, but we characterized the β subunit mutant with a 100-fold increase in HlyA resistance. Although the increase in resistance of the α₃ subunit mutant to LtxA was statistically significant, the biological relevance of that 2-fold increase is slight compared to the over 1,000-fold increase in LtxA resistance in the β-subunit mutant and is likely due to the significant decrease in the β subunit on the cell surface. Double, triple, and quadruple α subunit-encoding gene mutants also failed to be significantly altered in their HlyA sensitivity compared to the parental U-937 cells.

Earlier observations demonstrated that in natively expressing β₂ integrin leukocytes, β₂ integrins appear to require intracellular heterodimer formation for processing and glycosylation before there is cell surface expression (28, 29). We therefore were surprised that there was detectable β₂ subunit expression on the quadruple α subunit mutants. Upon further genetic manipulation and biochemical confirmation, we observed direct interaction with the β subunit and that the presence of the β subunit alone is enough to facilitate increased sensitivity to the cytotoxic activity of HlyA and LtxA. This work helps to clarify long-standing controversies in the HlyA and LtxA fields regarding the presence or absence of a receptor, although understanding the mechanism by which the interaction of either of these toxins with the β subunit enhances cytotoxic activity or the specific molecular interactions between the proteins remains to be understood.

Complementation of the ITGB2 mutants with either full-length ITGB2 or an ITGB2 recombinant missing the cytoplasmic tail of the β subunit was sufficient to confer sensitivity to RTX toxins HlyA and LtxA. The cytoplasmic tail is necessary for outside-in signaling via β₂ integrins when they engage their extracellular ligands (31). Therefore, we conclude that at least these two RTX toxins, HlyA and LtxA, engage and use the extracellular portion of the β₂ integrin β subunit to facilitate cytotoxicity. There are several different physiological effects that occur when cells are challenged with sublytic concentrations of HlyA; however, our results do not indicate whether signaling via the β subunit is involved in any of these events (12, 32, 33). Further investigation is required to clarify whether pore formation, facilitated by the β subunit interaction or independent of that, is the mechanism at the heart of sublytic host cell events.

Our results demonstrate that although the β₂ integrin β subunit enhances HlyA cytotoxic activity, HlyA cytotoxic activity is still observed on β₂-deficient cells at higher doses of toxin. This suggests that there may be a secondary receptor or receptor-independent activity for HlyA. At this point, we do not know if the host cellular events that occur with the HlyA β₂ integrin β subunit-dependent and -independent activities are similar. It is remarkable that for the related RTX toxin, LtxA cytotoxic activity is inversely linked with the surface expression of the β₂ integrin β subunit and that LtxA does not show detectable cytotoxic activity on the ITGB2 mutants at the highest LtxA concentrations that we can acquire. This suggests that LtxA either does not interact with a secondary receptor or lacks the receptor-independent activity. There is one significant phenotypic difference, erythrolysis, which differentiates HlyA and LtxA toxins. HlyA has potent activity toward erythrocytes, whereas LtxA has weak to nonexistent red cell lytic activity (34, 35). Glycophorin, a sialoglycoprotein, has been identified as a receptor for HlyA on erythrocytes, but its expression is limited to that cell type (36). We previously identified an insertion mutant in the HlyA repeat region (HlyA 829::PLQD) that retains 100% of the HlyA erythrolytic activity, but which lacks detectable leukolytic activity against BL3 cells, a bovine lymphoma cell line (37). Thorough genetic and biochemical studies of HlyA and LtxA will be required to identify the receptor-ligand interaction between these toxins and the β₂ integrin β subunit.

Based on our results, we present a model that may begin to explain how RTX toxins affect the pathogenesis of disease regardless of the specific niche occupied by the RTX toxin-expressing pathogen (Fig. 6). At the heart of the model is the acute sensitivity of leukocytes to these toxins. For HlyA-expressing UPEC strains that colonize the urinary
tract, leukocytes may be the first cells to be affected by this extracellular toxin. The need for just the β subunit without any structure provided by an α subunit indicates that all leukocytes are vulnerable whether they are monocytes, neutrophils, lymphocytes, or dendritic cells. Thus, the RTX toxins provide the relevant pathogens a global attack on both the innate and adaptive immune response. In the specific case of the UPEC HlyA exotoxin, its cytotoxic activity against cells lacking cell surface β2 integrins suggests to us that when UPEC cells are in close proximity to the epithelial barrier, locally high concentrations of HlyA can disrupt epithelial cells in order to aid deeper tissue invasion and possible systemic spread, supporting the clinical observation of the increased prevalence of HlyA in isolates from pyelonephritis and urosepsis. Therapeutically blocking the specific interaction of HlyA with β2 integrins may better allow the immune system access to overcome UPEC causing simple cystitis before the infection proceeds to a more severe and disseminated form.

**MATERIALS AND METHODS**

Bacterial strains, culture, and toxin preparations. Recombinant *E. coli* strain WAM1824 (described in reference 36), expresses the complete hlyCABD operon from a single plasmid (pSF4000), and wild-type HlyA was obtained by culturing this strain to an optical density at 600 nm (OD$_{600}$) of 0.8, pelleting bacterial cells, and filter-sterilizing culture supernatants through a 0.45-µm-pore syringe filter unit (Acrodisc 4508) or concentrating HlyA from culture supernatants by polyethylene glycol (PEG) precipitation as follows. WAM1824 was grown overnight at 37°C on LB agar plates containing 5% sheep red blood cells and 20 µg/ml chloramphenicol. Cells were swabbed from plates into 1 ml 1× PBS and diluted into 400 ml LB containing 20 µg/ml chloramphenicol and 2 mM CaCl$_2$ to an OD$_{600}$ of 0.05. Cultures were grown at 37°C with aeration to an OD$_{600}$ of 0.8. Cells were pelleted, and the supernatant was filtered through a 500-ml Nalgene Rapid-Flow aPES filtration unit. Protein was precipitated from supernatants by adding 200 g/liter PEG 3350 and 3% glycerol and stirring gently for 1 h at 4°C. Precipitated protein was pelleted by centrifugation at 9,700 × g at 4°C for 10 min. Pellets were resuspended in 0.85% saline, aliquoted in 100-µl single-use aliquots, and stored at −80°C. HlyA concentrations were determined by
comparison with a β-galactosidase standard of known concentration on Coomassie-stained polyacrylamide gels.

To obtain wild-type LtxA, Aggregatibacter actinomycetemcomitans strain Penn JP2 (a generous gift from S. Kachlany, originally described in reference 38) was grown for 48 h at 37°C in 0.4% CO2 on AAGM agar (dextrose, sodium bicarbonate, Trypticase soy, yeast extract, and agar) plates. A ΔhlyA JP2 derivative, generated in our lab by transformation with the suicide plasmid pKD378 (a generous gift from D. Kolodrubetz, described in reference 39), was grown for 48 h at 37°C in 0.4% CO2 on Columbia agar plates containing 5% sheep red blood cells and 100 μg/ml spectinomycin. Cells were swabbed from plates into 1 ml 1× phosphate-buffered saline (PBS) and diluted into 10 ml TSBYE (Trypticase soy broth and yeast extract) containing 1 mM CaCl2 to an OD600 of 0.05. Cultures were grown at 37°C with very slight aeration overnight to an OD600 of 0.4 to 0.6. Overnight cultures were diluted into 400 ml TSBYE containing 1 mM CaCl2 and grown overnight at 37°C with shaking at 50 rpm to an OD600 of 0.4 to 0.6. Cells were pelleted, and the supernatant was filtered through a 500-ml Nalgene Rapid-Flow aPES filtration unit. Protein was precipitated and LtxA quantified following the protocol outlined above for HlyA. Equivalent culture starting volumes and PEG-precipitated resuspension volumes were used from the ΔhlyA strain to serve as a control.

To obtain HpmA, recombinant E. coli strain WPM 184 (40, 41) was grown overnight at 37°C on LB agar plates containing 5% sheep red blood cells and 100 μg/ml carbenicillin. Cells were swabbed from plates into 1 ml 1× PBS and diluted into 25 ml LB containing 100 μg/ml carbenicillin to an OD600 of 0.05. Cultures were grown at 37°C with aeration to an OD600 of 0.8. Cells were pelleted, and the supernatant was filtered through a 0.45-μm syringe filter unit (Acrodisc 4508) before use in cytotoxicity assays. Staphylococcus aureus α-toxin was obtained from Sigma-Aldrich (catalog no. H9395) and resuspended in distilled water (dH2O) according to the manufacturer’s instructions.

Cell culture. Human kidney epithelial cells (A498 [42]), human T lymphocytes (Jurkat [43]), human B lymphocytes (Raji [44]), human promonocytic myeloid leukemia cells (U-937 [45]), and human bladder epithelial cells (5637 [46]) were cultured in RPMI 1640 (Gibco) with 10% heat-inactivated fetal bovine serum (Gibco), 1 mM sodium pyruvate (Gibco), 2 mM L-glutamine (Gibco), and 25 mM HEPES (Gibco) at 37°C under 5% CO2. Human embryonic kidney epithelial cells, HEK293T (47), were cultured in Dulbecco’s modified Eagle’s medium (DMEM [Corning]) with 10% heat-inactivated fetal bovine serum, 1 mM sodium pyruvate, and 2 mM L-glutamine at 37°C under 5% CO2.

Cytotoxicity assay. Culture supernatant containing PEG-precipitated RTX toxins and culture supernatant containing HpmA were incubated at various concentrations (2-fold dilutions) with the indicated cell lines at 1 × 106 to 2 × 107 cells/ml for 1 to 3 h at 37°C. S. aureus α-toxin was incubated with the indicated cell lines at 2 × 107 cells/ml for 24 h at 37°C. Cells were washed, and cell metabolism as a proxy for cell viability was measured by a standard XTT assay with colorimetric development of XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide at 0.5 mg/ml (Sigma)] with PMS (N-methyl dibenzopyrazine methyl sulfate; 3.8 mM) diluted in RPMI medium without phenol red (Sigma) (48). Cells were incubated with XTT solution at 37°C for 1 to 3 h before measuring absorbance at 450 nm. Results were normalized to cells treated with Triton X-100 as 100% death and RPMI alone as 0% death. CD64 values were determined, and statistics were performed in GraphPad Prism version 6.0 (GraphPad Software).

Library construction and selection. Human CRISPR Knockout Pooled Libraries (lentiCRISPRv2 backbone) no. 1000000048 and 1000000049 (Addgene) were used to generate lentivirus per the Zhang lab protocol (24). U-937 cells were transduced with lentivirus at a multiplicity of infection (MOI) of 0.3. Twenty-four hours posttransduction, cells were selected with 0.5 μg/ml puromycin and expanded for 8 days prior to freezing into aliquots of 6 × 105 cells/ml (500 × sgRNA representation) for library selection. Before use in library selection, aliquots were thawed and cells were recovered for 24 h. HlyA-containing supernatant (from WAM1824 cultures) was used to select library populations at a concentration resulting in ~95% cytotoxicity of wild-type U-937 cells (Fig. S1B). Following selection, viable cells were recovered and expanded under normal cell culture conditions. A total of 3 × 107 cells were frozen for DNA extraction, and an identical repeat selection with HlyA was performed on 6 × 107 cells. Viable cells from twice-selected populations were recovered and expanded under normal growth conditions to 3 × 107 cells for DNA extraction. Three biological replicates of library selections were performed, with two rounds of selection each (Fig. S1A).

DNA extraction, sequencing, and identification of selection hits. Genomic DNA from 3 × 107 cells was extracted from 2 representative vials of the parental library and the once- or twice-selected library populations for each replicate using the Qiagen Midi blood and cell culture kit according to the manufacturer’s protocol. To maintain diversity of the populations, 13 PCRs were performed for the parental populations and three PCRs for selected populations according to the following protocols. Libraries were PCR amplified for 16 cycles with v2adaptor primers (v2adaptor F/R) (see Table S2 in the supplemental material) to generate templates representing sgRNAs present in the different populations. These templates were PCR amplified for 24 cycles with a unique “barcoded” forward primer (F01 to F12) assigned to each library and a universal reverse primer (Runu) (Table S2). PCR products were visualized on a 1.2% agarose–ethidium bromide gel, relative band intensities were quantified by ImageJ, and equimolar amounts from replicate reactions were pooled. Pooled samples were separated on a 1.2% agarose–ethidium bromide gel and extracted with the QiaGen MinElute gel extraction kit, in a final buffer of Tris at pH 8.0 before sequencing. The second set of primers provided adaptors for Illumina sequencing, performed on a HiSeq2500 Rapid at the University of Wisconsin—Madison Biotechnology Core. Sequencing reads were demultiplexed, stagers introduced by unique barcodes were removed, and sequences from individual libraries were downloaded as individual files using the open-source web-based platform
Galaxy (usegalaxy.org). Individual library files were used for analysis with MAGeCK as described by the developers (25).

**Lentiviral cloning, production, and transduction.** Cloning into lentiCRISPR v2 was performed as described previously (24). Briefly, three sgRNA sequences from the GeCKO v2 library were used per target gene (Table S2). Oligonucleotide (Integrated DNA Technologies) were phosphorylated and annealed before being ligated into purified BsmBI (New England Biolabs)-cleaved and Fast-AP (Fermentas)-dephosphorylated lentiCRISPR v2. Ligation reactions were transformed into chemically competent Mach1 cells (Thermo Fisher Scientific), and plasmid sequences were validated by sequencing. To produce lentivirus, 1 µg each of packaging plasmids psPAX2 and pVSV-G was cotransfected with 1 µg of lentiCRISPR v2 containing sgRNA for target genes into 80% confluent HEK293T cells using TransIT-2020 (Mirus Bio, Madison, WI) according to the manufacturer’s protocol. After 72 h, virus-containing supernatants were harvested, and cell debris was removed by centrifugation at 5,000 × g for 5 min. Cleared supernatants were aliquoted and stored at –80°C.

U-937 cells were seeded the day before transduction to obtain 50% confluence the next day. On the day of transduction, 1.5 × 10⁶ cells were pelleted per transduction at 500 × g for 5 min. Supernatant was removed, and cells were resuspended directly in 100 µl virus-containing supernatant (described above) with 8 µg/ml Polybrene. Cells were incubated at 37°C for 2 h, gently rocking the tube every 15 min to resuspend cells. After 2 h, cells were transferred to a 12-well plate, and the volume was increased to 2 ml with complete cell medium. Cells recovered under normal growth conditions for 24 h before pelleting cells, discarding supernatant, and resuspending the cells in complete cell medium containing 0.5 µg/ml puromycin. Cells were maintained under normal growth conditions for 2 weeks before limiting dilution into 96-well plates to obtain clonal cell lines. Mutations were assessed by flow cytometry and indel detection by amplicon analysis (IDAA) and confirmed by Sanger sequencing.

Single-gene knockout U-937 cells were used to generate multisubunit knockouts. Custom gRNA fragments (CRISPR RNA [crRNA; Thermo Fisher]) were complexed with transactivating crRNA (tracrRNA) to generate sgRNAs according to the manufacturer’s protocol. Five micrograms of sgRNA was introduced by nucleofection according to the manufacturer’s protocol (Amaza nucleofector II; Lonza) into 1 × 10⁶ cells per intended mutation. Cells were recovered in complete medium for 24 h before undergoing limiting dilution into 96-well plates to obtain clonal cell lines. Mutations were assessed by flow cytometry and indel detection by amplicon analysis (IDAA) and confirmed by Sanger sequencing. This process was repeated in a stepwise fashion to obtain triple, quadruple, and quintuple gene knockouts.

**IDAA.** Fifty microliters of cells from growing clonal cell lines was pelleted at 500 × g for 10 min in a 96-well PCR plate. Supernatant was removed by flicking the plate, and cells were resuspended in 50 µl QExtract solution (Qiagen). DNA was extracted according to the manufacturer’s instructions. To dilute the generally viscous extracts, 150 µl dH₂O₂ was added to each well, and 1 µl of extracted DNA was used for PCR amplification. Indel detection by amplicon analysis (IDAA) was performed as described previously (27). Briefly, IDAA primers were designed to generate products between 200 and 600 bp surrounding the sgRNA target sequence of interest (Table S2). Forward primers were preceded with an M13 sequence to facilitate a tri-primer reaction to label products for analysis, including target specific forward and reverse primers and a 6-carboxyfluorescein (FAM)-labeled M13 primer in 1:10:10 ratio. PCR was performed in 20-µl reaction mixtures using 2 × GoTaq (Promega) using the cycling conditions described in reference 27. Dilutions (1:10) of the PCR product were submitted to the University of Wisconsin—Madison Biotechnology Center for fragment analysis on ABI3730 with a Chimerax Rox625 size standard. Raw data were analyzed with Peak Scanner Software version 3.0 (Applied Biosystems, Life Technologies Corporation).

**Flow cytometry.** Cells were counted on a TC20 cell counter (Bio-Rad), and 1 × 10⁶ cells were stained for analysis. Cells were surface stained with anti-α₁ (H1111; Biologend), anti-α₂ (ICRF464; Biologend), anti-α₃ (3.9; Biologend), and anti-β₂ (TS1/18, Biologend; MEM48, Thermo Fisher Scientific) and fixed using IC fixation buffer (Ebioscience). Samples were acquired using an LSRII flow cytometer with at least 50,000 events collected per sample (BD Biosciences) with fluorescence-activated cell sorter (FACS) DIVA software (BD Biosciences). FlowJo software version 10 was used to analyze data (Treestar).

**Far-Western blotting.** Recombinant human integrin α₁β₂ (3868-AV), human integrin α₁β₂ (5047-AM), human integrin α₂β₁ (5755-AI), and human ICAM-1/CD54 (720-IC) were obtained from R&D Systems. Recombinant proteins were resuspended according to the manufacturer’s instructions, aliquoted, and stored at −20°C. Five hundred nanograms of protein was separated per lane of a 4 to 20% gradient SDS-PAGE gel (Bio-Rad). Separated proteins were transferred to nitrocellulose. Membranes were blocked for 1 h, rocking, in 3% bovine serum albumin (BSA)–0.5% Tween 20 in 1× PBS. Membranes were incubated with PEG-precipitated HlyA or LtxA at 1 µg/ml in blocking buffer for 1 h at room temperature, rocking. Membranes were washed 5 times for 1 min each in PBS plus 0.5% Tween 20. Proteins were detected with primary antibodies in blocking buffer for 1 h at room temperature, rocking, against α₁ (CR38, 1:500; R&D Systems), α₂ (66519-1, 1:4000; Proteintech), α₂ (60258-1, 1:4000; Proteintech), β₂ (AF7130, 1:1000; R&D Systems), anti-HlyA polyclonal antibody (1:5,000 [49]), or a pool of anti-HlyA monoclonal antibodies (B7, 1:10,000; B9, 1:200; B10, 1:200; C7, 1:200; C10, 1:2,000; D1, 1:5,000; E2, 1:800; G3, 1:5,000; G8, 1:2,000; H10, 1:10,000 [49]). Secondary antibodies were diluted in blocking buffer and incubated for 1 h at room temperature, rocking; for the blot against α subunits and HlyA, the antibodies were donkey anti-rabbit 680RD and donkey anti-mouse 800CW, and for the blot against the β₂ subunit and HlyA or LtxA, the antibodies were donkey anti-goat 800CW and donkey anti-mouse 680RD (all secondary antibodies at 1:10,000; Licor). Anti-HlyA antibodies (monoclonal or polyclonal) equally detected HlyA, whereas only the anti-HlyA monoclonal pool cross-reacted with LtxA, so blots demonstrating direct interaction of the toxins with the β₂ subunit were performed with the HlyA monoclonal
antibody pool and a polyclonal anti-β₂ subunit antibody. Anti-α subunit antibodies were raised in mice, so the anti-HlyA rabbit polyclonal antibody was used to simultaneously detect both proteins in different channels. Membranes were dried between sheets of Whatman paper, and near-infrared images were captured on a Li-Cor Odyssey Fc imager.

**β₂ complements.** Full-length β₂ (amino acids [aa] 1 to 769) or a cytoplasmic tail deletion mutant (β₂-Dtail, aa 1 to 723) with 7 silent mutations within the 20-bp sgRNA recognition site for sgRNA-ITGB2-1 (to allow complementation without cleavage by the constitutively expressed Cas9 and sgRNA in the parental Δβ₂ cell line) were synthesized as gBlocks (IDT) with 20-bp overlaps to insert by Gibson assembly (NEB) into a BamHI-digested pcDNA3.1-hygromycin-resistant vector (Thermo Fisher Scientific). DNA was extracted from sequence-confirmed clones and elec troporated into a ΔNEB into a BamHI-digested pcDNA3.1-hygromycin-resistant vector (Thermo Fisher Scientific). DNA was elec troporated into a ΔNEB into a BamHI-digested pcDNA3.1-hygromycin-resistant vector (Thermo Fisher Scientific). DNA was elec troporated into a ΔNEB into a BamHI-digested pcDNA3.1-hygromycin-resistant vector (Thermo Fisher Scientific). DNA was

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.01459-19.

**FIG S1**, TIF file, 0.4 MB.

**FIG S2**, TIF file, 0.3 MB.

**FIG S3**, TIF file, 0.3 MB.

**FIG S4**, TIF file, 0.3 MB.

**TABLE S1**, PDF file, 0.03 MB.

**TABLE S2**, PDF file, 0.1 MB.

**ACKNOWLEDGMENTS**

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases and the National Institute of General Medical Sciences of the National Institutes of Health under Award numbers F32AI126900 (L.C.R.), T32AI55397 (L.C.R.), T32GM07215 (V.T.), R21AI125897 (A.M.), and R01AI137070 (J.-D.S.) and the Robert Turrell Endowment (R.A.W.), and services for single-cell sorting were supported by the University of Wisconsin Carbone Cancer Center Support Grant P30 CA014520. A.M. and J.-D.S. are Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease.

The authors thank the University of Wisconsin Biotechnology Center DNA Sequencing Facility for providing Illumina sequencing facilities and the University of Wisconsin Carbone Cancer Center Flow Cytometry core for providing single-cell sorting facilities and support services.

**REFERENCES**

1. Foxman B. 2003. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49:53–70. https://doi.org/10.1067/MDA.2003.7.

2. Stamm WE. 2002. Scientific and clinical challenges in the management of urinary tract infections. Am J Med 113(Suppl 1A):15–45.

3. Dudgeon LS, Wordley E, Bawtree F. 1921. On Bacillus coli infections of the urinary tract, especially in relation to haemolytic organisms. J Hyg (Lond) 20:137–164. https://doi.org/10.1017/s002217240003391x.

4. Bien J, Sokolova O, Bozko P. 2012. Role of uropathogenic Escherichia coli virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol 2012:681473. https://doi.org/10.1155/2012/681473.

5. Lavigne JP, Boitet-Dubois A, Laouini D, Combescure C, Bouziges N, Marès P, Sotto A. 1991. Virulence potential of Escherichia coli strains causing asymptomatic bacteriuria during pregnancy. J Clin Microbiol 29:3950–3953. https://doi.org/10.1128/JCM.29.12.3950-3953.1991.

6. Maris CF, Zhang L, Tallman P, Manning SD, Somsel P, Raz P, Colodner R, Jantunen ME, Sotto A, Saxen H, Foxman B. 2002. Variations in 10 putative urapathogenic virulence genes among urinary, faecal and periurethral Escherichia coli. J Med Microbiol 51:138–142. https://doi.org/10.1099/0022-1317-51-2-138.

7. Smith YC, Rasmussen SB, Grande KD, Conran RM, O’Brien AD. 2008. Hemolysin of urapathogenic Escherichia coli evokes extensive shedding of the uroepithelium and hemorrhage in bladder tissue within the first 24 hours after intraurethral inoculation of mice. Infect Immun 76:2978–2990. https://doi.org/10.1128/IAI.00075-08.

8. Johnsen N, Hamilton ADM, Greve AS, Christensen MG, Therkildsen JR, Wehmoller J, Skals M, Praetorius HA. 2019. α-Hemolysin production, as a single factor, causes fulminant sepsis in a model of Escherichia coli-induced bacteraemia. Cell Microbiol 21:e13017. https://doi.org/10.1111/cmi.13017.e13017.

9. Cavaleri SJ, Snyder IS. 1982. Cytotoxic activity of partially purified Escherichia coli alpha haemolysin. J Med Microbiol 15:11–21. https://doi.org/10.1099/00222615-15-1-11.

10. Bhakdi S, Greulich S, Muhly M, Eberspächer B, Becker H, Thiele A, Hugo F. 1989. Potent leukocidial action of Escherichia coli hemolysin mediated by permeabilization of target cell membranes. J Exp Med 169:737–754. https://doi.org/10.1084/jem.169.3.737.

11. Dhakal BK, Mulvey MA. 2012. The UPEC pore-forming toxin alpha-hemolysin triggers proteolysis of host proteins to disrupt cell adhesion, inflammatory, and survival pathways. Cell Host Microbe 11:58–69. https://doi.org/10.1016/j.chom.2011.12.003.

12. Wiles TJ, Dhakal BK, Eto DS, Mulvey MA. 2008. Inactivation of host Akt/protein kinase B signaling by bacterial pore-forming toxins. Mol Biol Cell 19:1427–1438. https://doi.org/10.1099/mcb.007-0638.

13. Lally ET, Kieba IR, Sato A, Green CL, Rosenbloom J, Korostoff J, Wang JF.
Shenker BJ, Ontell M, Robinson MK, Billsings PC. 1997. RTX toxins recognize a beta2 integrin on the surface of human target cells. J Biol Chem 272:30463–30469. https://doi.org/10.1074/jbc.272.48.30463.

Morova J, Osiack R, Masin J, Sebo P. 2008. RTX cytotoxins recognize beta2 integrin receptors through N-linked oligosaccharides. Proc Natl Acad Sci U S A 105:3535–3540. https://doi.org/10.1073/pnas.0711400105.

Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.

Munksgaard PS, Skals M, Reinholdt J, Poulsen K, Jensen MR, Yang C, Ristow et al. 2015. Valeva A, Walev I, Kemmer H, Weis S, Siegel I, Boukhallouk F, Wassenaar TM, Chavakis T, Bhadki S. 2005. Binding of Escherichia coli hemolysin and activation of the target cells is not receptor-dependent. J Biol Chem 280:36657–36663. https://doi.org/10.1074/jbc.M006792200.